Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 13, 2025, Dogwood Therapeutics, Inc. announced financial results for the second quarter of 2025 and provided a business update.</li><li>Enrollment in the Phase 2b trial of Halneuron for the treatment of Chemotherapy Induced Neuropathic Pain (CINP) has reached 52 patients.</li><li>An interim data readout is expected in the fourth quarter of 2025.</li></ul>

On August 13, 2025, Dogwood Therapeutics, Inc. announced financial results for the second quarter of 2025 and provided a business update.Enrollment in the Phase 2b trial of Halneuron for the treatment of Chemotherapy Induced Neuropathic Pain (CINP) has reached 52 patients.An interim data readout is expected in the fourth quarter of 2025.

DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron  Trial  Interim Read Out in 4Q25 